The percentage of NASs approved by CDER

Slides:

Advertisements

Similar presentations

Targeted Cancer Therapeutics, LLC Investor Presentation.

Advertisements

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

What is a Generic Medication?. The World Health Organization Definition of a Generic Medication A generic drug is a pharmaceutical product, usually intended.

SOURCES OF PHARMACEUTICAL INFORMATION. 1-Pharmacopeias Pharmacopoeia is a book containing an official list of the drugs used in medicine together with.

Professor Stuart Walker BSc PhD MFPM FIBiol FRSC FRCPath FIstD Director CMR International UK.

+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,

When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.

PHARMACOLOGY oScience of drugs oGreek words= pharmakon (drug) and logos (study) oDeals with interaction of exogenously administered chemical molecules.

Overview of FDA's Regulatory Framework for PET Drugs

WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Regulatory principles reflected in practice of WHO PQP Milan Smid,

Center for Drug Evaluation and Research (CDER) Tanya Eberle Kamal Diar David Clements.

Biologics and Genetic Therapies Directorate Health Products and Food Branch HEALTH CANADA Helping Canadians maintain and improve their health. Agnes Klein.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

First Lecture By Dr. Abdelkader Ashour, Ph.D. Dr. Amira Badr, Ph.D.

The pharmaceutical R&D process

1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.

Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.

Pharmaceutical Composition Claims and Enablement Robert J. Hill, Jr. Quality Assurance Specialist Technology Center

“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.

1 CHALLENGES IN REGULATION OF TRADITIONAL AND ALTERNATIVE MEDICINES 24 th March, 2010 MOHSW Conference Room Registration of Herbal Drugs.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,

Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.

Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.

Introduction to general pharmacology.

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

Clinical Trials — A Closer Look

Biotechnology Chemical Pharmaceutical Customer Partnership

FDA-CDRH in the Next Decade A Vision for Change

Introduction to Biosimilars

NASs approval time by therapeutic area:

Median 25th and 75th percentile

Biosimilar monoclonal antibodies Biologics are critical components in the treatment of patients with cancer. Biosimilars - biologics that are highly similar.

CHAWLA MEDICOS Present’s Branded v/s Generic medicine

Median approval time for new active substances approved by ICH agencies by approval year Methodology For each new active substance (NAS) approved between.

Comparing HTA recommendations

Percentage Key Message

2002–2006 Mid and Other sized companies continued to launch the majority of NMEs APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON.

Median submission gap, median approval time and percentage approved as expedited for new active substances (NASs) approved by six authorities:

Median time to internationalisation

This study was conducted using the CIRS EMaRReT database, which tracks new medicines and line extensions in 15 Emerging Markets (Argentina, Brazil, Mexico,

INTRODUCTION to Pharmacology

Comparison of median time for submission to EM countries from 1st world-wide approval ( vs ) Median time from 1st WW approval to submission.

New active substance median approval time for six regulatory authorities in Key messages The last decade, , saw a continuation.

Comparison of median approval time of NASs by year of submission vs

New active substances approved by EMA and FDA over 10 years

EMA: The European Medicines Agency

Insight into the Pharmaceutical Industry

Professional Organizations

NME/NAS launches in 2005/6 APRIL 2007

Biosimilars in Hematologic Oncology

Rollout time breakdown: 24 common NASs in 7 jurisdictions

INTERNATIONALISATION – FOCUS ON EMA AND FDA

Phase 2 to phase 3 clinical trial transitions: Reasons for success and failure in immunologic diseases Dhavalkumar D. Patel, MD, PhD, Christian Antoni,

Pipeline size of Major companies had grown at a steadier rate than that of smaller companies APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.

Development time for new molecular entities first launched onto the world market between MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS.

Cycle times decreased in larger but not smaller, companies

By Amany Helmy Hasanin Assistant Professor of Clinical Pharmacology

Opening an IND: Investigator Perspective

Median, Box : 25th and 75th percentiles

Assessment routes and timelines in Australia (2011)

Comparison of median approval time of NASs by year of submission vs

Introduction to Basic Research Methods

Out of the 52 NASs approved by all six authorities during :

Median times to submission and licensing for 70 new active substances approved in five markets from 1997 to 2010 Note: EMA approval.

Process mapping of registration to reimbursement for new pharmaceuticals in UK Description: A systematic methodology was developed in order to create the.

Assessment routes and timelines

Comparison of median time for submission to EM countries from 1st world-wide approval ( vs ) Median time from 1st WW approval to submission.

Presentation transcript:

The percentage of NASs approved by CDER by one-cycle review process has increased Median approval time of NASs approved by one-cycle review Percentage of NASs approved by one-cycle review according to priority designation Key Messages The overall median time for products approved after only review cycle (2001-2010) is 182 days for priority new active substances (NASs) and 304 days for standard NASs. The percentage of products approved after only one review cycle during 2001-2010 increased over the decade for both standards and priority NASs. Methodology For each NAS, the approval time by year of approval was calculated as the time taken from the date an application is received by CDER to the date of Legal Marketing. Median approval time of NASs approved by CDER by one-cycle review was calculated according to priority designation. The percentage of NASs approved by CDER by one-cycle review was calculated according to priority designation. Source: CIRS Regulatory Review Times Database New Active Substances (NAS): This includes chemical, biological and radiopharmaceutical substances that have not been previously available for therapeutic use in humans to be used for the cure, alleviation, treatment, prevention or in vivo diagnosis of diseases in humans. This term also includes: An isomer, mixture of isomers, a complex or derivative or salt of a chemical substance previously available as a medicinal product but differing in properties with regard to safety and efficacy from that substance previously available; a biological substance previously available as a medicinal product, but differing in molecular structure, nature of source material or manufacturing process; a radiopharmaceutical substance that is a radionuclide or a ligand not previously available as a medicinal product. Alternatively, the coupling mechanism linking the molecule and the radionuclide has not been previously available. Applications that are excluded from the study: Vaccine; any other application, where new clinical data were submitted; generic applications; those applications where a completely new dossier was submitted from a new company for the same indications as already approved for another company; applications for a new or additional name, or a change of name, for an existing compound (i.e. a ‘cloned’ application). CDER = United States Food and Drug Administration Center for Drug Evaluation and Research; NASs= new active substances.